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HIV and Hepatitis C Co-infection:
Trends and Changing Treatment
Two of the greatest challenges in health care are the chronic infections with hepatitis C virus (HCV) and human 
immunodeficiency virus (HIV).  They are currently the most prevalent blood-borne chronic viral infections in the 
United States and worldwide, and both carry high mortality and morbidity rates if left untreated.  In recent years 
there have been tremendous advances in the treatment and management of both viruses individually.  However, 
co-infection with HIV/HCV generally leads to a more complicated disease course: it reduces the effectiveness of 
treatment because HIV tends to accelerate the progression of HCV and decreases the patient’s susceptibility to the 
current HCV standard therapy of interferon and ribavirin.  Currently, little data exists describing the population 
co-infected with HIV/HCV.  But with the recent approval of two new oral drugs by the FDA for the treatment of 
hepatitis C and the promise of more to follow, understanding the population dynamics of HIC/HCV co-infected 
individuals has become much more important for future treatment.  Using the patient information collected by Mr. 
Charles Hansen, Dr. Timothy Lane and their partners at the Regional Center for Infectious Disease in Greensboro, 
North Carolina, where over a thousand HIV-infected patients receive care yearly, we were able to analyze the cohort 
of HIV infected patients who are co-infected with HCV.  This co-infected cohort is approximately 10% of the total 
who are HIV-infected.  It is our hope that these data will better the understanding of HIV/HCV co-infection and 
improve the standard of therapy.  
Introduction
HIV is the retrovirus responsible for causing Acquired Immuno-
deficiency Syndrome (AIDS), a progressive failure of the human 
immune system resulting from HIV virus infection and destruc-
tion of vital immune system cells.  HIV alone is one of the most 
destructive pandemics in human history, with the World Health 
Organization (WHO) estimating that over 25 million people have 
succumbed to AIDS between 1981, the year of its first recogni-
tion, through 2011 (7).  At the end of 2010, it was estimated that 
34 million people worldwide are living with the disease, with a 
disproportionate number living in sub-Saharan Africa (7).  That 
number continues to rise as the disease continues to spread at a rate 
estimated to be around 2.6 million new infections a year (5).  For-
tunately, treatments are available; for instance, the effectiveness 
of highly active antiretroviral therapy (HAART) improves the life 
expectancy of persons already infected.  
 HCV infection is even more widespread with an estimat-
ed 130-170 million people infected worldwide and an estimated 3 
million new infections per year (6).  With 4.1 million infected in 
the United States alone, HCV has become the leading cause for 
liver transplantation in the U.S. and is on track to surpass alco-
holic liver disease as the leading cause of liver-related death (1). 
There are six known genotypes of HCV, distinguished from each 
other based on the composition of virus RNA.  Genotype 1 is the 
most common in North America and also the most difficult to treat 
with the current interferon therapy (1).  In addition to infection 
by genotype 1 HCV, other diagnostic factors that negatively af-
fect responsiveness to interferon-based therapy include old age, 
African American ethnicity, an IL28B TT haplotype of the human 
interferon gene, alcohol consumption, advanced liver fibrosis, and 
HIV co-infection due to the resulting low CD4 lymphocyte counts. 
Fortunately, unlike the hepatitis B virus and HIV, which can build 
up reservoirs of their genetic code within the host’s genome, HCV 
does not integrate its genetic material into the host’s.  Without 
these dormant stores of genetic code, which are difficult, if not im-
possible, to eradicate, it is possible to attain permanent sustained 
virologic response (SVR) for most HCV infected patients if suc-
cessful combinative therapies could be developed.  SVR is defined 
as long term suppression of viral RNA below detectable levels.  It 
is anticipated that a SVR of a year or longer will portend a prob-
able cure, but it is relatively early in the era of antiviral treatment 
of HCV. 
 Co-infection with HCV and HIV presents a greater chal-
lenge to treat than either of the two infections individually.  It is 
estimated that 4 to 5 million people worldwide are suffering from 
a chronic infection of the two viruses.  Co-infection is character-
ized by increased rates of disease progression and decreased re-
sponsiveness to standard therapy.  In a recent review published in 
the Journal of the American Medical Association, only about 30% 
of patients with HIV/HCV co-infection receiving pegylated inter-
feron (peginterferon) and ribavirin treatment developed an SVR 
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(1).  In comparison, approximately 55% of patients with only HCV 
infection developed SVR after receiving the same treatment (1). 
Besides being more resistant to treatment, HIV/HCV co-infection 
is associated with accelerated development of fibrosis, cirrhosis, 
end-stage liver disease, and hepatocellular carcinoma.  This accel-
eration could be due to the problematic reactive oxygen species or 
oxidants that are produced by the very active infections of HIV and 
HCV, resulting from the lower CD4 counts and other immunosup-
pressing effects associated with the course of HIV infection.  Ad-
ditionally, co-infection treatment is further hampered by complica-
tions from ribavirin and HIV anti-retroviral agents.  Fortunately, 
HCV infection does not seem to alter the course of HIV infection 
and progression to AIDS.  A 2002 study showed HCV infection 
does not significantly alter the risk of death, development of AIDS, 
or a positive response to HIV antiviral treatment (4).  
The current standard of treatment for chronic HCV infection is 
a 48-week regimen of peginterferon with ribavirin.  The treatment 
subjects the patient to an unpleasant experience due to the side 
effects of interferon, including flu-like symptoms and depression, 
and suffers from only a 40-50% chance of success in achieving an 
SVR (2).
Two new drugs, telaprevir (Incivek) and boceprevir (Victrelis), 
have shown tremendous improvement in the percentage of pa-
tients who achieved an SVR compared to those who only received 
standard therapy with peginterferon and ribaviran.  Both drugs are 
nonstructural 3/4A serine protease inhibitors that target multiple 
steps of the HCV life cycle.  In a recent double-blind randomized 
trial, teleprevir plus standard therapy showed an 83% SVR (2).  A 
similar trial of boceprevir showed an SVR of 68% (3).  With both 
drugs showing significant improvement over the current standard 
of therapy, it is likely that they will become part of a new standard 
regimen.  It will thus be important to identify and understand the 
populations that are co-infected and to anticipate challenges in de-
livering such improved therapies. 
Results  
Extensive data on patients co-infected with HCV and HIV has 
been collected from the medical records of patients receiving 
treatment at the Regional Center for Infectious Disease (RCID) 
in Greensboro, North Carolina.  Over a thousand patients receive 
HIV treatment currently at the RCID, and approximately 10% of 
the patients are co-infected with HCV.  The age, years since HIV 
diagnosis, HCV/ HIV viral loads, and CD4 count are analyzed and 
subdivided according to gender and ethnicity to provide a better 
description of the co-infected population.  
 
The co-infected sample comprises of 49 African American 
males (44%), 15 white males (14%), 37 African American females 
(34%) and 9 white females (8%).  The data indicates a higher co-
infection rate in African Americans regardless of gender, which is 
consistent with studies in other locales and is supported by large 
population surveys, such as the U.S. National Health and Nutrition 
Assessment.
The average age of the entire group was 51.7 years with a stan-
dard deviation of +2.42 years.  Both African American males and 
females tend to be a few years older than their white counterparts, 
though this slight difference is not significant.
 
 
Figure 1: Average age of co-infected patients.  p = 0.896 by 
Chi-square with 3 degrees of freedom.
Also remarkable is the consistency in the years since diagnosis. 
In the co-infected sample, an average of 14.21 years has passed 
since the original HCV diagnosis.  The standard deviation here 
is +2.71 years, slightly larger than the average age standard de-
viation.  Again there is slight difference between African Ameri-
cans and whites, with white males being diagnosed about 3 years 
before African American males and white females about 3 years 
after African American females. This difference, however, is not 
significant.
 
Figure 2: Average years since HCV diagnosis. p = 0.671 by 
Chi-square with 3 degrees of freedom.
Taken together, the data suggests that this sample of co-infected 
patients is very homogenous.  As a group, the majority was born 
sometime in the late 1950s and early 1960s and was likely exposed 
to the high-risk practices that occurred in the 1970s and 1980s. 
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Blood transfusion histories were not available in the co-infected 
cohort and would be another possible source of HCV infection 
since HCV testing of donated blood did not begin until approxi-
mately 1990.  With the development of HCV screening, the ma-
jority was diagnosed in the mid to late 1990s and only very few 
(10 patients of the 117 in this sample group) have received any 
treatment for HCV, mainly because of cost and fear of side-effects. 
These HCV infections have clearly been present for some time but 
now there is cause for some optimism for those with HCV.  If one 
patient were to have a positive response to the new therapies and 
achieve an HCV SVR, then the remaining and relatively homo-
geneous population would also be good candidates for treatment.   
A few notable differences do arise when comparing the latest 
average HCV/HIV viral loads and average CD4 counts between 
ethnicities and genders.  White males and females have the lowest 
(1.9 million IU/mL) hepatitis C viral loads based on testing done 
an average of 4.4 years ago. They are followed by those of Afri-
can American females (5 million IU/mL), while African American 
males have the highest average viral load (6.3 million IU/mL). 
This further suggests that African American ethnicity is a negative 
prognostic factor for hepatitis C virus and may partially explain 
the 10%-15% lower SVR rates to the new HCV antivirals com-
pared to the response in white populations.   
Figure 3: Average hepatitis C viral load in IU/mL
HIV viral loads and CD4 counts taken an average of 0.4 years 
ago show that white males have an average viral load of 803 copies 
of HIV RNA /mL, with 67% having undetectable (<48 copies of 
RNA/mL) levels of the virus in their blood, and an average CD4 
count of 558/ml.  68% of African American females in the co-
infected sample have undetectable HIV RNA levels and an aver-
age CD4 count of 504/ml.  49% of African American males in the 
co-infected sample have undetectable viral loads and an average 
CD4 count of 443/ml.  Finally, only 33% of white females in the 
co-infected sample display undetectable HIV viral loads and an 
average CD4 count of 466/ml.  
Overall, it appears that white males tend to have overall better 
control of their HIV infection in terms of lower HIV viral loads 
and higher CD4 counts.  Breaking the trend seen in HCV viral 
loads, African American females appear to be the second healthi-
est subgroup followed by African American males.  White females 
seem to have the least control of their HIV infections.  These dif-
ferences among the subgroups could be attributed to a wide variety 
of factors, including difference in treatment history, social issues, 
economic status, accessibility of care, and differences in ethnicity. 
Though these are interesting trends, their usefulness in determin-
ing who will benefit from the new HCV treatment is limited as the 
teleprevir and boceprevir studies were not conducted with HIV co-
infected person. Until studies are done analyzing HCV treatment 
response with regard to HIV progression, this data can only offer 
a unique demographic breakdown of the co-infected population.
Figure 4: Average HIV viral load in copies/mL
 
Figure 5: Average CD4 count in cells/mL
Conclusion  
 Analyzing patient statistics can offer a wealth of informa-
tion by illuminating trends in disease progression.  Physicians can 
use these patterns to tailor individual treatment based on group 
factors that prove to be beneficial or detrimental to treatment suc-
cess.  In the cohort of co-infected HIV and HCV patients studied 
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here, it was determined that the group was remarkably similar in 
age and the number of years since HCV diagnosis.  This suggests 
that if one patient were to have a positive response to the new treat-
ment, the remaining patients are likely to as well.  If the homoge-
neity of HIV/HCV co-infection were to extend beyond the sample 
studied here, patients around the globe might have equally high 
chances of success.
In the next few years, telaprevir and boceprevir will likely be-
come part of the standard of treatment for chronic HCV.  Both are 
expensive drugs: $55,500 for 12 weeks and $28,500 for 24 weeks, 
respectively.  With one in four patients in this population without 
any type of health insurance, it is crucial that populations who will 
potentially benefit from these treatments be identified and access 
to treatment be provided.  Through improvements in medicine and 
further research in HCV and its co-infection with HIV, it may be 
possible to obtain sustained virologic responses in a much larger 
proportion of patients.  Additionally, because humans are the only 
known natural hosts for HCV, it is theoretically possible with im-
proving treatments for HCV to be eradicated from the global popu-
lation.
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